Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: First human experience with a sirolimus-eluting collagen membrane (Coll-R)

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 1219-1224

  Paulson, William D ^a,b   Kipshidze, Nicholas ^c   Kipiani, Konstantine ^d   Beridze, Nutsa ^d   DeVita, Maria V ^e   Shenoy, Surendra ^f   Iyer, Sriram S ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Department of Cardiovascular Medicine   (Georgia)

^d Bokhua Center of Angiology and Vascular Surgery   (Georgia)

^e LENOX HILL HOSPITAL   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hemodialysis access; Neointimal hyperplasia; Sirolimus; Thrombosis; Vascular access

Indexed keywords

POLITEF; RAPAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING DISORDER; BLOOD VESSEL WALL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; FALSE ANEURYSM; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT PATENCY; HEMODIALYSIS; HUMAN; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR ACCESS; VEIN ANASTOMOSIS; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; COLLAGEN; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; POLYTETRAFLUOROETHYLENE; RENAL DIALYSIS; SAFETY; SIROLIMUS; SURVIVAL RATE; THROMBOSIS; VASCULAR PATENCY; YOUNG ADULT;

EID: 84861151056     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr667     Document Type: Article

References (41)

1. Roy-Chaudhury P, Sukhatme VP, Cheung K. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol 2006; 17: 1112-1127
2. Li L, Terry CM, Yan-Ting ES et al. Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int 2008; 74: 1247-1261
3. Lee T, Roy-Chaudhury P. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis 2009; 16: 329-338
4. Hodges TC, Fillinger MF, Zwolak RM et al. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997; 26: 1009-1019
5. Cinat ME, Hopkins J, Wilson SE. A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. Ann Vasc Surg 1999; 13: 191-198
6. Miller PE, Carlton D, Deierhoi MH et al. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000; 36: 68-74
7. Gibson KD, Gillen DL, Caps MT et al. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the USRDS Dialysis Morbidity and Mortality Study. J Vasc Surg 2001; 34: 694-700
8. Dixon BS, Beck GJ, Vazquez MA et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360: 2191-2201
9. Chang CJ, Ko PJ, Hsu LA et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004; 43: 74-84
10. Levit RD, Cohen RM, Kwak A et al. Asymptomatic central venous stenosis in hemodialysis patients. Radiology 2006; 238: 1051-1056
11. Yevzlin A, Asif A. Stent placement in hemodialysis access: Historical lessons, the state of the art and future directions. Clin J Am Soc Nephrol 2009; 4: 996-1008
12. Haskal ZJ, Trerotola S, Dolmatch B et al. Stent graft versus balloon angioplasty for failing dialysis-access grafts. N Engl J Med 2010; 362: 494-503
13. Allon M, Lockhart ME, Lilly RZ et al. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60: 2013-2020
14. Asif A, Roy-Chaudhury P, Beathard GA. Early arteriovenous fistula failure: a logical proposal for when and how to intervene. Clin J Am Soc Nephrol 2006; 1: 332-339
15. Dixon BS. Why don't fistulas mature? Kidney Int 2006; 70: 1413-1422
16. Dember LM, Beck GJ, Allon M et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis. J Am Med Assoc 2008; 299: 2164-2171
17. Allon M, Lok CE. Dialysis fistula or graft: the role for randomized clinical trials. Clin J Am Soc Nephrol 2010; 5: 2348-2354
18. Lacson E, Lazarus JM, Himmelfarb J et al. Balancing fistula first with catheters last. Am J Kidney Dis 2007; 50: 379-395
19. Nugent HM, Groothuis A, Seifert P et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res 2002; 39: 524-533
20. Conte MS, Nugent HM, Gaccione P et al. Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study. J Vasc Surg 2009; 50: 1359-1368
21. Kelly B, Melhem M, Zhang J et al. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant 2006; 21: 2425-2431
22. Lee BH, Nam HY, Kwon T et al. Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol Dial Transplant 2006; 21: 2432-2438
23. Clinical Trials.gov. Safety Study of the Vascular Wrap TM Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access. Sponsor: Angiotech Pharmaceuticals Identifier: NCT01033357
24. Charron T, Nili N, Strauss BH. The cell cycle: a critical therapeutic target to prevent vascular proliferative disease. Can J Cardiol 2006; 22 (Suppl B): 41B-55B
25. Zhu W, Masaki T, Cheung AK et al. In-vitro release of rapamycin from a thermosensitive polymer for the inhibition of vascular smooth muscle cell proliferation. J Bioequiv availab 2009; 1: 3-12
26. Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50: 1299-1304
27. Yachi S, Tanabe K, Tanimoto S et al. Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimuseluting stents versus bare-metal stents in hemodialysis patients. Am J Kidney Dis 2009; 54: 299-306
28. Weisz G, Leon MB, Holmes DR et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS Trial. J Am Coll Cardiol 2009; 53: 1488-1497
29. Kawatsu S, Oda K, Saiki Y et al. External application of rapamycineluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg 2007; 84: 560-567
30. Schachner T, Zou Y, Oberhuber A et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 2004; 77: 580-585
31. Streit F, Christians U, Schiebel HM et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC: electrospray-mass spectrometry. Clin Chem 1996; 42: 1417-1425
32. Ram SJ, Nassar R, Work J et al. Risk of hemodialysis graft thrombosis: analysis of monthly flow surveillance. Am J Kidney Dis 2008; 52: 930-938
33. Allon M, Robbin ML. Hemodialysis vascular access monitoring: current concepts. Hemodial Int 2009; 13: 153-162
34. Paulson WD, Work J. Controversial vascular access surveillance mandate. Semin Dial 2010; 23: 92-94
35. Paulson WD, Moist L, Lok CE. Vascular access surveillance: an ongoing controversy. Kidney Int 2012; 81: 132-142
36. Kahan BD, Napoli KL, Kelly PA et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109
37. Van Beusekom HMM, Saia F, Zindler JD et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 2007; 28: 974-979
38. Van der Giessen WJ, Sorop O, Serruys PW et al. Lowering the dose of sirolimus, released from non polymeric hydroxyapatite coasted coronary stent, reduces signs of delayed healing. JACC Cardiovasc Interv 2009; 2: 284-290
39. Roine E, Bjork IT, Oyen O. Targeting risk factors for impaired wound healing and wound complications after kidney transplantation. Transplant Proc 2010; 42: 2542-2546
40. Cheung AK, Terry C, Li L. Pathogenesis and local drug delivery for prevention of vascular access stenosis. J Ren Nutr 2008; 18: 140-145
41. Li L, Terry CM, Blumenthal DK et al. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant 2007; 22: 3139-3146